Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100058 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
A Phase 2 study of Obesity and Overweight, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
- 20
- Study locations
NCT03100058: Completed Phase 2 study of Obesity and Overweight, sponsored by Novartis Pharmaceuticals.
NCT03100058 is a Phase 2 study of Obesity and Overweight that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 460 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03100058, a Phase 2 study of Obesity and Overweight, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.
Primary Outcome
Dose-response relationship of two dose regimens of LIK066 as measured by the percent change from baseline in body weight relative to placebo after 24 weeks of treatment
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LIK066
Study Locations (20)
California
- Novartis Investigative Site - Beverly Hills
- Novartis Investigative Site - Carmichael
- Novartis Investigative Site - Concord
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Northridge
- Novartis Investigative Site - Roseville
- Novartis Investigative Site - San Ramon
- Novartis Investigative Site - Stockton
- Novartis Investigative Site - Walnut Creek
Florida
- Novartis Investigative Site - Bradenton
- Novartis Investigative Site - Fort Lauderdale
- Novartis Investigative Site - Port Charlotte
- Novartis Investigative Site - West Palm Beach
Alabama
- Novartis Investigative Site - Anniston
- Novartis Investigative Site - Jasper
Colorado
- Novartis Investigative Site - Denver
- Novartis Investigative Site - Golden
Georgia
- Novartis Investigative Site - Athens
- Novartis Investigative Site - Augusta
Hawaii
- Novartis Investigative Site - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2017-05-06 |
| Est. Completion | 2018-08-02 |
| Phase | Phase 2 |
What the finished NCT03100058 record still lists
NCT03100058 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03100058 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03100058 about?
NCT03100058 is a clinical study titled "A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults". This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.
What is the current status of trial NCT03100058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2017-05-06. Estimated completion is 2018-08-02.
What conditions does trial NCT03100058 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT03100058?
The interventions under investigation include: Placebo (DRUG), LIK066 (DRUG).
Who is sponsoring clinical trial NCT03100058?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03100058 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03100058's enrollment target sits among peer trials
460 149th of 1053 higher than 903 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI